Roxadustat Phase III programme pooled analyses showed positive efficacy and no increased cardiovascular risk in patients with anaemia from chronic kidney disease
11 November 2019 07:00 GMT Roxadustat Phase III programme pooled analyses showedpositive efficacy and no increased cardiovascular risk inpatients with anaemia from chronic kidney disease In non dialysis-dependent patients receiving roxadustat, the risk ofMACE, MACE+ and all-cause mortality was comparable to placebo Dialysis-dependent patients receiving roxadustat had a lower risk of MACE+and no increased risk of MACE or all-cause mortality versus epoetin alfa In incident dialysis patients, roxadustat had a lower risk of MACE and MACE+ andshowed a trend towards